ARTICLE | Emerging Company Profile

Affinivax: MAPS for vaccines

Affinivax using MAPS technology to make more effective, less complex vaccines

November 3, 2014 8:00 AM UTC

Affinivax Inc. is developing vaccines for bacterial infections that it says could provide universal protection regardless of disease serotype and be more immunogenic, cheaper and less complex to manufacture than traditional subunit conjugate vaccines. The lead program is focused on pneumococcus.

The company debuted last week with $4 million in equity seed funding from the Bill & Melinda Gates Foundation...